Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients

Recruiting now · Not applicable

Conditions studied: Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer, Lung Cancer

In brief

GALENOS 2 is a single-arm, single-center, phase II interventional study designed to evaluate the effects of a galenic immunonutrition dietary supplement in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment. The study aims to assess whether the formula may reduce treatment-related toxicity and improve treatment compliance, using patients from the GALENOS 1 observational study as the control group for comparison

Key facts

Study ID

NCT07514754

Run by

Fondazione del Piemonte per l'Oncologia

People needed

52

Starts

2025-10-03

Expected to finish

2027-12-30

Last updated by the study team

2026-04-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent to study procedures
• Male or female, age greater than 18 years
• Histological or cytological documentation of head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer candidate for immunotherapy, chemotherapy, and/or radiotherapy according to standard clinical practice
• ECOG Performance Status score less than 2
• Adequate kidney, liver, and bone marrow function
• Ability to understand, sign informed consent, and comply with study procedures

You may not qualify if…

• Incomplete recovery from surgery before starting antineoplastic treatment
• Other progressing malignancy or malignancy requiring active treatment within the last 3 years, except localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ
• Active infection requiring systemic antibiotic therapy
• Serious or unstable medical conditions, psychiatric disorders, or substance abuse interfering with study compliance
• Receipt of any live vaccine within 30 days before study treatment
• Active cardiac pacing/pacing implants/neurostimulators/hearing system not compatible with bioimpedance analysis
• Edema and/or ascites not compatible with body weight evaluation and bioimpedance analysis
• Enteral or parenteral nutritional support at baseline

Where it is running

• Fondazione del Piemonte per l'Oncologia- IRCCS Istituto di Candiolo, Candiolo, Turin 10060 — Candiolo, Torino (TO), Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.